Oct. 8, 2013
/PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company with marketing applications for its lead product OMS302 for use during lens replacement surgery currently under review in both the US and
, today announced the appointment of
Michael K. Inouye
as vice president, commercial operations.
Mr. Inouye has over 20 years of management experience in the pharmaceutical industry. His experience includes positions as senior vice president, corporate and commercial development for Pharmacyclics, and senior vice president, commercial operations at Telik. Prior to that, he was senior vice president of commercial operations at Gilead Sciences from 1995 to 2004 where he developed and led the worldwide commercial organization through four product launches while Gilead grew from a research and development organization to an international commercial company. Before Gilead, he was vice president sales and marketing at InSite Vision, an ophthalmic drug delivery company. Prior to his biopharma experience he held management positions of increasing responsibility in sales, marketing and business development over 13 years at Merck US Human Health. From 2005 through its acquisition by Gilead in 2012, Mr. Inouye served on the board of directors of Pharmasset.
"We are very pleased that Mike has joined Omeros," said
Gregory A. Demopulos
, M.D., Omeros' chairman and chief executive officer. "With his deep expertise in building commercial organizations and his proven track record of successful drug-product launches, Mike is an important part of our team as we prepare for and execute the 2014 planned launch of OMS302. Given his breadth of experience, I expect that Mike will also play a key role in advancing the rest of our pipeline toward commercialization."
"The strength of Omeros' management team and the potential of its product pipeline are impressive," stated Mr. Inouye. "OMS302 represents the beginning of Omeros' transition from an R&D organization to a commercial company, and I am honored to play a role in this phase of corporate growth."